Bio Techne Operating Margin vs. Net Income

TECH Stock  USD 68.40  2.04  3.07%   
Based on the measurements of profitability obtained from Bio Techne's financial statements, Bio Techne Corp may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in February. Profitability indicators assess Bio Techne's ability to earn profits and add value for shareholders.

Bio Techne Operating Profit Margin

0.0717

As of now, Bio Techne's Price Sales Ratio is increasing as compared to previous years. As of now, Bio Techne's Net Income From Continuing Ops is increasing as compared to previous years. The Bio Techne's current Non Operating Income Net Other is estimated to increase to about 61.5 M, while Accumulated Other Comprehensive Income is forecasted to increase to (51.2 M). The Bio Techne's current Gross Profit is estimated to increase to about 954.3 M, while Pretax Profit Margin is projected to decrease to 0.07.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.560.58
Sufficiently Down
Slightly volatile
Net Profit Margin0.05150.0542
Notably Down
Slightly volatile
Operating Profit Margin0.07170.0755
Notably Down
Slightly volatile
Pretax Profit Margin0.0690.0727
Notably Down
Slightly volatile
Return On Assets0.03140.033
Notably Down
Slightly volatile
Return On Equity0.04180.044
Notably Down
Slightly volatile
For Bio Techne profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bio Techne to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bio Techne Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bio Techne's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bio Techne Corp over time as well as its relative position and ranking within its peers.

Bio Techne's Revenue Breakdown by Earning Segment

Check out World Market Map.
The next projected EPS of Bio Techne is estimated to be 0.5633 with future projections ranging from a low of 0.53 to a high of 0.6. Bio Techne's most recent 12-month trailing earnings per share (EPS TTM) is at 0.49. Please be aware that the consensus of earnings estimates for Bio Techne Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Bio Techne is projected to generate 0.5633 in earnings per share on the 31st of March 2026. Bio Techne earnings estimates show analyst consensus about projected Bio Techne Corp EPS (Earning Per Share). It derives the highest and the lowest estimates based on Bio Techne's historical volatility. Many public companies, such as Bio Techne, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Bio Techne Revenue Breakdown by Earning Segment

By analyzing Bio Techne's earnings estimates, investors can diagnose different trends across Bio Techne's analyst sentiment over time as well as compare current estimates against different timeframes.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.143
Dividend Share
0.32
Earnings Share
0.49
Revenue Per Share
7.762
Quarterly Revenue Growth
(0.01)
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bio Techne Corp Net Income vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bio Techne's current stock value. Our valuation model uses many indicators to compare Bio Techne value to that of its competitors to determine the firm's financial worth.
Bio Techne Corp is rated second in operating margin category among its peers. It is rated fourth in net income category among its peers making up about  434,834,123  of Net Income per Operating Margin. As of now, Bio Techne's Operating Profit Margin is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Techne's earnings, one of the primary drivers of an investment's value.

Bio Techne's Earnings Breakdown by Geography

Bio Net Income vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Bio Techne

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.17 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Bio Techne

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
73.4 M
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Bio Net Income Comparison

Bio Techne is currently under evaluation in net income category among its peers.

Bio Techne Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bio Techne, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bio Techne will eventually generate negative long term returns. The profitability progress is the general direction of Bio Techne's change in net profit over the period of time. It can combine multiple indicators of Bio Techne, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-53.9 M-51.2 M
Operating Income117.6 M113.1 M
Income Before Tax113.2 M114.2 M
Total Other Income Expense Net-4.4 M-4.1 M
Net Income84.4 M89.2 M
Income Tax Expense28.8 M27.4 M
Net Income Applicable To Common Shares328.1 M344.5 M
Net Income From Continuing Ops84.4 M155.3 M
Non Operating Income Net Other58.6 M61.5 M
Interest Income3.5 M1.8 M
Net Interest Income-4.2 M-4.4 M
Change To Netincome-42.8 M-40.6 M
Net Income Per Share 0.47  0.42 
Income Quality 3.53  3.70 
Net Income Per E B T 0.67  0.58 

Bio Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bio Techne. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bio Techne position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bio Techne's important profitability drivers and their relationship over time.

Bio Techne Earnings Estimation Breakdown

The calculation of Bio Techne's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Bio Techne is estimated to be 0.5633 with the future projection ranging from a low of 0.53 to a high of 0.6. Please be aware that this consensus of annual earnings estimates for Bio Techne Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
0.53
Lowest
Expected EPS
0.5633
0.60
Highest

Bio Techne Earnings Projection Consensus

Suppose the current estimates of Bio Techne's value are higher than the current market price of the Bio Techne stock. In this case, investors may conclude that Bio Techne is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Bio Techne's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2026Current EPS (TTM)
1589.02%
0.0
0.5633
0.49

Bio Techne Earnings History

Earnings estimate consensus by Bio Techne Corp analysts from Wall Street is used by the market to judge Bio Techne's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Bio Techne's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Bio Techne Quarterly Gross Profit

190.19 Million

As of now, Bio Techne's Retained Earnings are increasing as compared to previous years. The Bio Techne's current Price Earnings Ratio is estimated to increase to 104.34, while Retained Earnings Total Equity is projected to decrease to under 812.3 M. The Bio Techne's current Net Income Applicable To Common Shares is estimated to increase to about 344.5 M, while Common Stock Shares Outstanding is projected to decrease to under 169.4 M.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bio Techne's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
66.0868.1770.26
Details
Intrinsic
Valuation
LowRealHigh
59.5961.6875.24
Details
15 Analysts
Consensus
LowTargetHigh
63.7070.0077.70
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.530.560.60
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Bio assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Bio Techne. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Bio Techne's stock price in the short term.

Bio Techne Earnings per Share Projection vs Actual

Actual Earning per Share of Bio Techne refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Bio Techne Corp predict the company's earnings will be in the future. The higher the earnings per share of Bio Techne, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Bio Techne Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Bio Techne, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Bio Techne should always be considered in relation to other companies to make a more educated investment decision.

Bio Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Bio Techne's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
2025-11-05
2025-09-300.430.42-0.01
2025-08-06
2025-06-300.50.530.03
2025-05-07
2025-03-310.510.560.05
2025-02-05
2024-12-310.390.420.03
2024-10-30
2024-09-300.380.420.0410 
2024-08-07
2024-06-300.490.490.0
2024-05-01
2024-03-310.450.480.03
2024-02-01
2023-12-310.410.4-0.01
2023-10-31
2023-09-300.440.41-0.03
2023-08-08
2023-06-300.550.550.0
2023-05-03
2023-03-310.530.530.0
2023-02-02
2022-12-310.620.47-0.1524 
2022-11-01
2022-09-300.590.45-0.1423 
2022-08-04
2022-06-300.520.51-0.01
2022-05-04
2022-03-310.50.540.04
2022-02-01
2021-12-310.450.470.02
2021-11-02
2021-09-300.430.460.03
2021-08-05
2021-06-300.430.470.04
2021-05-06
2021-03-310.390.450.0615 
2021-02-02
2020-12-310.340.410.0720 
2020-11-05
2020-09-300.270.360.0933 
2020-08-04
2020-06-300.190.250.0631 
2020-04-30
2020-03-310.290.350.0620 
2020-02-04
2019-12-310.280.27-0.01
2019-10-29
2019-09-300.260.270.01
2019-08-06
2019-06-300.330.31-0.02
2019-04-30
2019-03-310.290.30.01
2019-02-05
2018-12-310.250.270.02
2018-10-30
2018-09-300.240.250.01
2018-08-07
2018-06-300.320.340.02
2018-05-02
2018-03-310.290.30.01
2018-02-06
2017-12-310.230.260.0313 
2017-10-31
2017-09-300.220.230.01
2017-08-08
2017-06-300.250.270.02
2017-05-02
2017-03-310.230.240.01
2017-02-07
2016-12-310.210.2-0.01
2016-10-31
2016-09-300.20.210.01
2016-08-17
2016-06-300.240.23-0.01
2016-05-03
2016-03-310.220.250.0313 
2016-02-02
2015-12-310.210.220.01
2015-10-28
2015-09-300.210.2-0.01
2015-08-06
2015-06-300.220.220.0
2015-05-05
2015-03-310.230.22-0.01
2015-02-03
2014-12-310.210.210.0
2014-10-28
2014-09-300.220.21-0.01
2014-08-11
2014-06-300.210.220.01
2014-04-28
2014-03-310.220.240.02
2014-02-04
2013-12-310.20.19-0.01
2013-10-29
2013-09-300.20.210.01
2013-08-06
2013-06-300.210.210.0
2013-04-30
2013-03-310.220.220.0
2013-02-05
2012-12-310.190.190.0
2012-10-23
2012-09-300.20.19-0.01
2012-07-31
2012-06-300.210.2-0.01
2012-05-01
2012-03-310.220.230.01
2012-01-31
2011-12-310.20.19-0.01
2011-10-25
2011-09-300.210.2-0.01
2011-08-02
2011-06-300.190.210.0210 
2011-05-03
2011-03-310.20.210.01
2011-02-01
2010-12-310.170.170.0
2010-10-26
2010-09-300.180.180.0
2010-08-03
2010-06-300.180.17-0.01
2010-05-04
2010-03-310.20.19-0.01
2010-02-02
2009-12-310.170.170.0
2009-10-28
2009-09-300.180.180.0
2009-08-04
2009-06-300.170.170.0
2009-04-28
2009-03-310.180.190.01
2009-02-03
2008-12-310.160.160.0
2008-10-22
2008-09-300.160.190.0318 
2008-08-05
2008-06-300.170.180.01
2008-04-29
2008-03-310.170.190.0211 
2008-01-29
2007-12-310.140.150.01
2007-10-24
2007-09-300.140.140.0
2007-08-07
2007-06-300.140.140.0
2007-05-01
2007-03-310.150.150.0
2007-01-30
2006-12-310.120.120.0
2006-10-25
2006-09-300.120.130.01
2006-08-08
2006-06-300.120.120.0
2006-04-25
2006-03-310.120.130.01
2006-01-31
2005-12-310.10.110.0110 
2005-10-27
2005-09-300.10.110.0110 
2005-08-16
2005-06-300.110.120.01
2005-04-26
2005-03-310.110.110.0
2005-02-01
2004-12-310.090.090.0
2004-10-21
2004-09-300.090.090.0
2004-08-10
2004-06-300.090.08-0.0111 
2004-04-27
2004-03-310.080.090.0112 
2004-01-27
2003-12-310.070.080.0114 
2003-10-23
2003-09-300.070.080.0114 
2003-08-12
2003-06-300.070.080.0114 
2003-05-01
2003-03-310.070.080.0114 
2003-01-28
2002-12-310.060.060.0
2002-10-25
2002-09-300.060.060.0
2002-08-13
2002-06-300.060.070.0116 
2002-04-23
2002-03-310.060.060.0
2002-01-29
2001-12-310.050.050.0
2001-10-18
2001-09-300.050.050.0
2001-08-14
2001-06-300.050.060.0120 
2001-05-01
2001-03-310.050.050.0
2001-01-30
2000-12-310.040.040.0
2000-10-24
2000-09-300.040.040.0
2000-08-15
2000-06-300.040.050.0125 
2000-04-25
2000-03-310.030.050.0266 
2000-02-08
1999-12-310.030.030.0
1999-10-21
1999-09-300.030.030.0
1999-08-10
1999-06-300.030.030.0
1999-04-26
1999-03-310.030.030.0
1999-02-02
1998-12-310.080.090.0112 
1998-10-22
1998-09-300.070.090.0228 
1998-08-11
1998-06-300.110.130.0218 
1998-04-28
1998-03-310.090.10.0111 
1998-02-03
1997-12-310.080.080.0
1997-10-23
1997-09-300.080.080.0
1997-08-12
1997-06-300.080.090.0112 
1997-04-22
1997-03-310.070.080.0114 
1997-01-28
1996-12-310.060.060.0
1996-10-24
1996-09-300.060.060.0
1996-08-15
1996-06-300.070.070.0
1996-04-22
1996-03-310.060.070.0116 

Use Bio Techne in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Techne position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Techne will appreciate offsetting losses from the drop in the long position's value.

Bio Techne Pair Trading

Bio Techne Corp Pair Trading Analysis

The ability to find closely correlated positions to Bio Techne could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Techne when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Techne - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Techne Corp to buy it.
The correlation of Bio Techne is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Techne moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Techne Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Techne can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bio Techne position

In addition to having Bio Techne in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Debt ETFs Thematic Idea Now

Broad Debt ETFs
Broad Debt ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Debt ETFs theme has 296 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Debt ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:
To fully project Bio Techne's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bio Techne Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bio Techne's income statement, its balance sheet, and the statement of cash flows.
Potential Bio Techne investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Bio Techne investors may work on each financial statement separately, they are all related. The changes in Bio Techne's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bio Techne's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.